Julie Steenhuysen and Michael Erman

(Reuters) – Johnson & Johnson (NYSE:) expects to file for approval of 14 new drugs by 2025, and has projected average peak sales of $4 billion a year for each, a top J&J scientist said ahead of a strategy review of the company’s pharmaceuticals unit on Thursday.

Among the top pipeline assets, Mathai Mammen, global head of research for J&J’s Janssen pharmaceutical division, pointed to a drug combination for non-small cell lung cancer, an anticoagulant it is developing with partner Bristol Myers (NYSE:) Squibb and a vaccine for respiratory syncytial virus (RSV).

J&J said last week that it plans to spin off its consumer health division that sells Listerine and Band-Aid bandages in order to focus on pharmaceuticals and medical devices in the biggest shakeup in the U.S. company’s 135-year history https://www.reuters.com/article/johnson-johnson-restructuring-timeline/how-johnson-johnson-became-the-sprawling-healthcare-giant-it-is-today-idUSKBN2HX2D7.

Interview with Mammen: He said that he didn’t think the transaction would affect research and development spending.

“We’re really happy and proud of the way R&D is functioning – the strategy we’re using and the level of investments,” he said.

J&J developed one of the three COVID-19 vaccines authorized in the United States, but its use in the country tailed off sharply after rare cases of blood clotting were linked to the shot.

Nonetheless, Mammen said J&J still expects to develop more vaccines using the same adenovirus vector technology.

Mammen explained that the drug induces more than just short-lived antibodies. It also produces good, many types of T cells… which gives you a really lasting benefit.

Mammen stated that the company is “actively considering” a variety of technology platforms including messenger DNA, which forms the basis of COVID-19 vaccines. Moderna (NASDAQ: Pfizer (NYSE:) Partner BioNTech

He said, “We currently have many technologies and we will look into expanding them further.”